The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance


Vascular endothelial growth factor (VEGF) has become a major target in cancer treatment as it promotes tumor angiogenesis. Therapy with anti-VEGF antibody bevacizumab reportedly induces high levels of circulating VEGF which may potentially contribute to resistance. Based on animal or computational models, mechanisms of VEGF induction by bevacizumab have… (More)
DOI: 10.18632/oncotarget.11084


9 Figures and Tables